Suchergebnisse - "Xia, Zhongjun"

PubPharm (4)

1

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301) : a randomised, double-blinded, placebo-controlled, phase 3 trial

enthalten in: BMC cancer | 2023

von Xia, Z. | Leng, Y. | Fang, B. | +51

2

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH) : a phase II, single-arm study

enthalten in: BMC medicine | 2022

von Qiu, L. | Xia, Z. | Fu, C. | +20

3

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

enthalten in: International journal of hematology | 2021

von Du, J. | Fang, B. | Li, J. | +16

4

Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial : a multi-center study

enthalten in: Annals of hematology | 2020

von Li, J. | Bao, L. | Xia, Z. | +17

1
[1]